85 results about "Carbohydrate tolerance" patented technology

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

The invention provides application of a product of targeted Vasorin protein in preparation of a product for diagnosing or treating kidney diseases with reduced glucose tolerance, and belongs to the technical field of biological medicines. Vasorin is used as a biomarker of the hypoglucose tolerance nephropathy, the level of Vasorin in urine of a patient is absolutely quantified through an ELISA technology, and the Vasorin has great clinical value and practical significance in early discovery and intervention of the hypoglucose tolerance nephropathy. According to the present invention, the gene or the Vasorin protein for controlling the Vasorin expression is adopted as the target spot, and the specific vector is adopted to perform overexpression on the Vasorin protein, such that the lipid droplet deposition and the reactive oxygen species (ROS) overgeneration in the renal tubular epithelial cell can be effectively improved, and the albumin reabsorption ability of the renal tubular can be improved so as to effectively treat the glucose tolerance reduced nephropathy.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

The invention relates to mulberry oligosaccharide, a preparation method thereof and application of the mulberry oligosaccharide in blood sugar regulation and control. The mulberry oligosaccharide is obtained by processing mulberries through a large number of researches and specific process steps of enzymolysis, selenic acid modification, plasma treatment and the like, so that the stability of the mulberry oligosaccharide can be obviously improved, the inhibition capability on alpha-glucosidase is obviously improved, the sugar tolerance condition of diabetic mice is improved, the blood sugar level is stabilized, and the application prospect is wide. Meanwhile, the insulin sensitivity of the body can be improved, the insulin resistance degree can be improved, the absorption and utilization of insulin to glucose can be improved, the SOD activity of the body can be improved, and the MDA content can be reduced, so that the development of diabetes can be effectively slowed down. In addition, natural mulberry is used as a main preparation raw material, no harmful chemical component is added, the cost is low, the safety is good, and great social significance is achieved.

The invention discloses application of a fucoidin degradation product Fuc-S in a pharmaceutical composition for preventing, relieving or treating type 2 diabetes mellitus and liver injury, and relates to the technical field of biological medicines. The invention provides a new effect of fucoidin Fuc-S in treating diabetic liver injury, and particularly, the fucoidin Fuc-S can significantly improve blood glucose control (reducing fasting blood glucose and enhancing sugar tolerance) and blood lipid spectrum (reducing TG, TC and LDL-C and increasing HDL-C) of diabetic mice, alleviate liver fatty degeneration and reduce serum ALT / AST level, and shows a significant liver protection effect. Furthermore, the Fuc-S can be used for remodeling the intestinal flora structure through specific enrichment of beneficial bacteria such as Bacteroides acdifaciens and the like, so that the generation of short-chain fatty acid (SCFAs) with a liver protection effect is promoted. The flora and metabolic change jointly improve the oxidative stress state of the liver, inhibit pro-inflammatory response and reduce lipid accumulation. The invention provides a novel nutrition intervention strategy for prevention and treatment of T2DM and liver complications thereof.

The invention discloses a probiotic agent for relieving prediabetic action and application thereof, and belongs to the technical field of microorganisms. Experiments prove that bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics can relieve the prediabetic stage, which is specifically embodied in reducing weight gain of mice in the prediabetic stage, regulating blood sugar metabolism, improving sugar tolerance and insulin resistance, protecting liver and pancreas tissues, being beneficial to increasing the diversity of intestinal flora, recovering the structure of the intestinal flora, and improving the immunity of the mice in the prediabetic stage. The invention also provides a preparation method of the bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics. The bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics. And the growth of beneficial bacteria related to metabolic disorder is enriched and regulated. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The invention discloses highly acetylated glucomannan and application thereof in preparation of a product with an effect of relieving prediabetes mellitus, and belongs to the technical field of medicines. In-vivo experiments prove that the glucomannan with high acetylation degree has the effect of relieving the prediabetic stage, which is specifically reflected in weight gain of mice in the prediabetic stage, regulation of blood glucose metabolism, improvement of glucose tolerance and insulin resistance, regulation of blood lipid metabolism, protection of liver and pancreatic tissues and reduction of epididymal fat cell size. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

The invention provides application of nitraria tangutorum bobr extract in preparation of products for regulating glycolipid metabolism disorder, and relates to the technical field of plant extract application. The nitraria macrocarpa extract is a composition rich in alkaloid and flavonoid compounds, wherein the sum of the content of total alkaloid and the content of total flavonoids is not lower than 85% of the total weight of the extract. The extract is prepared through the processes of fresh fruit juicing, alcohol precipitation impurity removal and AB-8 macroporous resin gradient elution. Experiments show that the extract can significantly reduce fasting blood glucose of type 2 diabetes mice induced by high-fat and high-sugar diet combined with STZ, improve sugar tolerance and insulin resistance, and synchronously regulate the blood fat level, and shows an excellent glucose and lipid metabolism synergistic improvement effect. The extract disclosed by the invention provides a choice for developing a safe and effective glycolipid metabolism regulator.

The application discloses a composition containing burdock polysaccharide for reducing blood sugar of type 2 diabetes patients and a preparation method and application thereof, and belongs to the technical field of medicine and food. The composition contains burdock polysaccharide, chitooligosaccharide, chlorogenic acid, epicatechin, resveratrol, ginsenoside Rd, and vitamin D, vitamin B1, vitamin B6, vitamin B12, magnesium glycinate and thaumatin protein. The application takes burdock polysaccharide as a core long-acting component, takes chitooligosaccharide as a short-acting synergistic component, constructs a long-short-acting synergistic blood sugar reducing system, and realizes the organic combination of rapid blood sugar reduction and stable blood sugar control. Experiments show that the composition can significantly reduce the fasting blood sugar of type 2 diabetes model rats, improve insulin resistance and glucose tolerance, reduce blood lipid and inflammatory factor levels, and reduce oxidative stress damage. The alpha-glucosidase inhibitory activity and in-vivo comprehensive blood sugar reducing effect of the composition are better than those of single burdock polysaccharide, and the composition has good taste and is suitable for long-term use of diabetes patients.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

The application discloses a mesenchymal stem cell preparation expressing FOXO3 and FGF21 and application thereof, relates to biological medicine, and a parent plasmid carrying a therapeutic gene of the mesenchymal stem cell expressing FOXO3 and FGF21 has a nucleotide sequence as shown in SEQ ID No: 01; the application provides a mesenchymal stem cell preparation capable of simultaneously expressing FOXO3 and FGF21, which can effectively improve insulin glucose tolerance, effectively reduce the content of glycosylated hemoglobin, and has the potential to treat human type 2 diabetes.

The application discloses an application of lactobacillus reuteri BNCC186563 in prevention and improvement of related diseases caused by high-fat diet and belongs to the technical field of microorganisms. It is found that the lactobacillus reuteri BNCC186563 can synergistically activate a PPAR alpha signal pathway and remodel a glycerophospholipid metabolism network, and the lactobacillus reuteri BNCC186563 can be used as a potential medicine, health care product and functional food for preventing and improving related diseases caused by high-fat diet, such as obesity, impaired glucose tolerance, insulin resistance, abnormal lipid metabolism, liver lipid accumulation, liver damage, inflammation and hyperlipidemia.

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The invention relates to a low glycemic index composition which comprises the following components in percentage by weight: 10-35% of a protein composition, 20-55% of a fat composition, 5-35% of a saccharide composition, 1-15% of a dietary fiber composition, 1-2% of a trace element composition, 0.1-1.5% of a vitamin composition and 5-20% of a macroelement composition, according to the composition with the low glycemic index, all the components are scientifically compounded, the digestion and absorption speed of carbohydrates is effectively controlled, the blood glucose level of diabetic patients or patients with impaired glucose tolerance is effectively controlled, comprehensive and balanced nutrition is provided for the diabetic patients or the patients with impaired glucose tolerance, and the composition is beneficial for repairing and improving the immunity of the diabetic patients or the patients with impaired glucose tolerance; and the feed also has the advantages of excellent quality uniformity, stability and fluidity, light taste, suitability for tube feeding and the like.

The invention discloses an application of miR-100 sponge in preparation of a medicine for treating type 2 diabetes mellitus. The miR-100 sponge can inhibit miR-100 in a targeted manner and close the expression of miR-100 in beta cells. The nucleic acid construct is further prepared from the nucleic acid construct, AAV8-mmu-miR-100 Sponge (AAV-Sponge) is injected into pancreatic ducts of obese diabetes mellitus mice, after treatment is conducted for 4 weeks, it is found that the sugar tolerance of the mice in a treatment group is improved, the GSIS function of beta cells is improved, and the nucleic acid construct is expected to be further applied to preparation of the medicine for treating the type 2 diabetes mellitus. The problems that current treatment methods for type 2 diabetes mellitus are deficient and the treatment cost is high are solved.

The present application discloses a two-arm branched fatty acid side chain, a receptor agonist modified therewith, and a use thereof. By adjusting the number and structure of side chain arms of the fatty acid chain, optimizing the type of a core molecule, and using the fatty acid chain to modify a receptor agonist, the present application significantly improves the physical and chemical stability of the receptor agonist and the therapeutic effect of the receptor agonist on reducing blood glucose and body weight. The fatty acid chain and the receptor agonist modified therewith disclosed in the present application can reduce blood glucose levels and improve sugar tolerance and has the effects of controlling appetite, food intake, and caloric intake, increasing energy consumption, preventing weight gain, promoting weight loss, and reducing excess body weight. In addition, the fatty acid chain and the receptor agonist modified therewith disclosed in the present application have relatively long half-life and can effectively prolong in vivo drug actions.

This invention discloses a probiotic protein V2016 and its application in the preparation of drugs for treating obesity, belonging to the field of biomedical technology. This invention provides a probiotic protein V2016, the amino acid sequence of which is shown in SEQ ID NO.1. Verification has shown that protein V2016 can efficiently and stably bind to the intestinal receptor ICAM-2, thereby significantly upregulating GLP-1 expression, mediating weight loss, reduced fat accumulation, and improved glucose tolerance; simultaneously, it can also reduce hepatic lipid deposition and inflammation, and promote thermogenesis activation in adipose tissue; at the intestinal microecological level, protein V2016 can improve the intestinal microenvironment, promote the enrichment of butyrate-producing bacteria in the intestine, thereby playing a role in regulating metabolism. In summary, the protein V2016 provided by this invention can be applied to the development of novel functional foods or weight-loss drugs.

The application discloses a traditional Chinese medicine composition for treating obesity and application. The traditional Chinese medicine composition comprises 4-8 parts of pericarpium citri reticulatae, 4-8 parts of fructus mume, 8-12 parts of dendrobium, 8-12 parts of lablab albumus, 13-17 parts of malt, 4-8 parts of hawthorn, 13-17 parts of buzhaye, and 1-5 parts of stevia rebaudiana. The traditional Chinese medicine composition has the following advantages: good curative effect on blood lipid abnormality, impaired glucose tolerance, especially fat metabolism abnormality caused by obesity, and can obviously improve the clinical symptoms of the obese patients; the traditional Chinese medicine composition has the effects of invigorating the spleen and eliminating fat, has no obvious damage to liver function, and has a protection function, and therefore, the safety is high. Therefore, the traditional Chinese medicine composition can be used for treating obesity.

The application provides application of a preparation targeting a Vasorin protein in preparation of a diagnosis or treatment product for impaired glucose tolerance kidney disease, and belongs to the technical field of biological medicine. Vasorin is used as a biomarker for impaired glucose tolerance kidney disease, and absolute quantification of the level of Vasorin in urine of patients through ELISA technology has great clinical value and practical significance for early discovery and intervention of impaired glucose tolerance kidney disease. Taking a gene controlling expression of Vasorin or the Vasorin protein as a target, overexpression of the gene or the protein by using a specific carrier can effectively improve lipid droplet deposition in renal tubular epithelial cells, excessive generation of reactive oxygen species (ROS), and the ability of the renal tubular epithelial cells to reabsorb albumin, so that effective treatment of impaired glucose tolerance kidney disease is achieved.

This invention relates to the field of clinical evaluation technology, specifically a stratified randomized controlled trial method for evaluating the intervention of traditional Chinese medicine compound formulas in prediabetes. The method includes the following steps: constructing stratified codes for subjects based on fasting blood glucose differences; constructing a blood glucose change difference sequence by combining the differences before and after intervention; using a regression function to obtain characteristic inflection points and establish a dose interval mapping relationship; obtaining the peak blood glucose time based on glucose tolerance tests and segmenting the time axis; calculating the slope characteristic parameters of each segment; and classifying and judging the comprehensive parameters and mapping relationship to construct a efficacy grading evaluation index. In this invention, by comparing multiple fasting blood glucose differences with stable parameters to extract fluctuation characteristics, a stratified coding mechanism is constructed to avoid the risk of stratification mismatch in a single test. The intervention difference is extracted and used to introduce piecewise linear regression to calculate the slope and capture the response characteristic inflection points. Combined with standard comparison, the degree of recovery of the body is determined, and the curve shape is transformed into a multi-dimensional efficacy grading index, effectively improving clinical precision.

The invention discloses lignin-triiodothyronine self-assembled particles as well as a preparation method and application thereof. The lignin-triiodothyronine composite nano particles are prepared from lignin and triiodothyronine in a joint self-assembly mode. Experiments prove that single in-situ injection of the lignin-triiodothyronine composite nanoparticles can increase the expression of subcutaneous adipose tissues UCP-1 of normal diet fed mice and reduce adipose cells; single in-situ injection can increase the expression of subcutaneous adipose tissue UCP-1 of a mouse fed with short-term high-fat diet, reduce the weight of adipose tissue, increase the energy consumption of the mouse and improve the glucose tolerance of the mouse; multiple times of in-situ injection can improve obesity and fatty liver caused by long-term high-fat diet. The lignin-triiodothyronine composite nanoparticle provided by the invention has a good application prospect in treating, relieving or improving obesity or metabolic diseases related to the obesity.

The invention discloses application of NPC1 protein or a reagent for promoting expression of the NPC1 protein in preparation of a medicine for treating MASLD, belongs to the technical field of biological medicine, reveals that the NPC1 is a key target of autophagic flow downstream retardation in the MASLD for the first time, discovers a brand new functional domain of the NPC1, breaks through the traditional cognition that the NPC1 is only used as cholesterol transporter, and provides a new application of the NPC1 in preparation of the medicine for treating the MASLD. And a synergistic treatment scheme of upstream activation and downstream dredging is provided. In-vivo experiments prove that the fatty degeneration of the liver can be obviously alleviated by combined strategy or TFEB agonist single-drug treatment, and the TFEB agonist can also effectively improve MASLD related sugar tolerance impairment.

The invention discloses application of indoleacetic acid in diagnosis and treatment of gestational diabetes mellitus. Clinical queue research finds that the concentration of serum indoleacetic acid of pregnant women in a gestational diabetes mellitus group is remarkably lower than that of pregnant women in a healthy control group, and high diagnosis efficiency is achieved. Animal experiments further prove that in a high fat diet induced mouse model with gestational diabetes mellitus, the exogenous indoleacetic acid is supplemented, so that the fasting blood glucose of a female mouse with gestational diabetes mellitus can be reduced, abnormal glucose tolerance and insulin resistance can be improved, and the indoleacetic acid is free of embryotoxicity, safe and reliable. The application provides a new thought and means for early diagnosis and effective treatment of gestational diabetes mellitus, and has a wide application prospect.

The application relates to the field of biological medicine, and discloses an application of pachyman-derived extracellular vesicles and high-abundance miRNA thereof in relieving obesity. Cell experiments and animal experiments find that the pachyman-derived extracellular vesicles and high-abundance miRNA thereof can up-regulate the expression amount of key genes for brownification of white fat in 3T3-L1 adipocytes and mice in vivo, significantly improve glucose tolerance and insulin resistance of obese mice, and obviously relieve liver steatosis and lipid accumulation. Not only can the pachyman-derived extracellular vesicles and high-abundance miRNA thereof improve obesity from a phenotype, but also can regulate lipid metabolism, and have the value of being applied to preparation of medicines for preventing or relieving obesity and related metabolic complications.

Disclosed are peptides that are useful as agonists of GPR56. Also disclosed are compositions comprising at least two synthetic or recombinant peptides, each of the peptides comprising a sequence selected from LLSSR, GYYCG, and NQGCKL, or a sequence that has a sequence identity of at least 60% thereto, wherein when a peptide comprises sequence a) or b) the peptide has a length of from 5-25 amino acids and wherein when a peptide comprises sequence c) the peptide has a length of from 6-26 amino acids. The compositions are useful for treating diseases or conditions such as vascular dysfunction, cardiovascular disease, impaired pancreatic -cell function, type II diabetes, impaired glucose tolerance, liver dysfunction, cirrhosis, liver cancer, depression, Alzheimer's disease, retinopathy and Attention deficit hyperactivity disorder.

The invention specifically discloses application of RNA binding protein FXR1 as a target spot in preparation of products for preventing and treating metabolism-related fatty liver diseases and improving glucose and lipid metabolism disorders, and relates to the technical field of biological medicines. By constructing a liver specific knockout mouse (HKO) and high-fat and high-sugar diet induction model, the invention reveals that the RNA binding protein FXR1 is a key pathogenic factor for liver fatty degeneration and metabolic disorder for the first time, and discovers that the deletion of the RNA binding protein FXR1 can significantly improve liver lipid deposition, alleviate liver injury and fibrosis, and can be used for treating liver fatty degeneration and metabolic disorder. The invention can improve the abnormal glucose tolerance and insulin resistance of the whole body, and inhibit the RNA binding protein FXR1 as a new strategy for treating liver glycolipid metabolism and metabolism-related fatty liver diseases.

Methods for treating diseases and disorders treatable by AMPK activation with cefin-1 and related compounds, such as metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, muscle loss, neuromuscular disorders, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular disease, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, eye diseases or disorders, ocular angiogenesis, β-hemochromocytic disorder, cancer, fibrosis, cancer cachexia, and mitochondrial diseases.

The application discloses application of calyculostero in preparation of blood sugar reducing drugs, and belongs to the technical field of pharmacological action of calyculostero. Experimental results show that the calyculostero can inhibit the activity of pancreatic alpha-amylase (IC50 is 4.34+ / -1.10 ug / mL) in a dose-dependent manner, reduce postprandial blood sugar, and improve sugar tolerance, reduce fasting blood sugar, improve total cholesterol and triglyceride levels, and reduce histopathological changes of liver, pancreas and kidney in long-term intervention, and has no obvious hepatotoxicity. The calyculostero can be used alone or together with a pharmaceutically acceptable excipient to prepare a pharmaceutical composition, and is used for reducing blood sugar or treating diabetes, and the dosage form includes oral preparations, injections and the like. The application provides a new natural medicine selection for drug treatment of diabetes.